Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

British Journal of Dermatology

Volumn 178, Issue 1, 2018, Pages 132-139

  Gordon, K B ^a   Blauvelt, A ^b   Foley, P ^c,d   Song, M ^e   Wasfi, Y ^e   Randazzo, B ^e   Shen, Y K ^e   You, Y ^e   Griffiths, C E M ^f  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d SKIN AND CANCER FOUNDATION   (Australia)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; APREMILAST; BRIAKINUMAB; BRODALUMAB; CYCLOSPORINE; EFALIZUMAB; ETANERCEPT; ETRETIN; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 23; IXEKIZUMAB; METHOTREXATE; PLACEBO; PROTEIN P19; SECUKINUMAB; TOFACITINIB; USTEKINUMAB; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MULTICENTER STUDY; PSORIASIS;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PSORIASIS; TREATMENT OUTCOME;

EID: 85037985932     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.16008     Document Type: Article

References (32)

1. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58:106–15.
2. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304–12.
3. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366:1367–74.
4. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
5. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
6. Griffiths CEM, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
7. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
8. Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
9. Blauvelt A, Papp KA, Griffiths CEM et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405–17.
10. Krueger JG, Ferris LK, Menter A et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015; 136:116–24.e7.
11. Papp K, Thaci D, Reich K et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol 2015; 173:930–9.
12. Reich K, Armstrong A, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418–31.
13. Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 2009; 10:319–24.
14. Adsit S, Zaldivar ER, Sofen H et al. Secukinumab is efficacious and safe in Hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials. Adv Ther 2017; 34:1327–39.
15. Tsai YC, Tsai TF. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol 2016; 151:412–31.
16. Cassano N, Galluccio A, De Simone C et al. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. J Biol Regul Homeost Agents 2008; 22:233–7.
17. Downs AMR. Switching between antitumour necrosis factor alpha biologic agents – is patient weight an important consideration? Br J Dermatol 2009; 160:1123–4.
18. Driessen RJ, Boezeman RJB, van de Kerkhof PCM, de Jong EMGJ. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160:670–5.
19. Esposito M, Mazzotta A, Saraceno R et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22:219–25.
20. Gordon K, Korman N, Frankel E et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54:S101–11.
21. Naldi L, Addis A, Chimenti S et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217:365–73.
22. Lebwohl M, Yeilding N, Szapary P et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010; 63:571–9.
23. Lonnberg AS, Skov L, Skytthe A et al. Association of psoriasis with the risk for Type 2 diabetes mellitus and obesity. JAMA Dermatol 2016; 152:761–7.
24. Blome C, Gosau R, Radtke MA et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 2016; 308:69–78.
25. Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75:77–82.
26. Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
27. Rich P, Karpov A, Papavassilis C et al. Secukinumab efficacy stratified by body weight: a subanalysis from the ERASURE study. J Am Acad Dermatol 2014; 70:AB186.
28. Szepietowski J, Rich P, Loeffler J et al. Secukinumab 300 mg shows superior efficacy across subject body weight groups: pooled analysis of phase 3 ERASURE and FIXTURE trials. J Am Acad Dermatol 2015; 72:AB248.
29. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125:61–7.
30. Eissing L, Radtke MA, Zander N, Augustin M. Barriers to guideline-compliant psoriasis care: analyses and concepts. J Eur Acad Dermatol Venereol 2016; 30:569–75.
31. Doshi JA, Takeshita J, Pinto L et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol 2016; 74:1057–65.e4.
32. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm 2015; 21:874–88.